CF Pharma
ActiveCF Pharma has been active since 2012 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €47k and a net result of €24k. Equity is growing by ~16.6% per year across the filed fiscal years. Its solvency ranks better than 27% of 15868 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.7% (low).
Checked score
Score 2024
63
/ 100
Healthy
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2023
Profitability55▲+23
Solvency34▼-4
Growth78=
Track record100
Bankruptcy probability, 12 months
0.7%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €2.5k at 30 days acceptable
Liquidity short (current ratio 0.65 against 0.82 in 2023; short-term debt: 24.5% of total assets), and 91.1% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 46
Relative position
BE, all sectors
reference
Sector 46
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2024Solvency, return and age of the figures
Solvency
8.9%
Return on assets
4.6%
Age of the figures
21 mo
neutral · Filed after the deadline
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 26-08-2025, 26 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filingsDeviation from the deadline
2025
not confirmed
2024
26 d late
2023
30 d late
2022
3 d early
2021
29 d late
2020
4 d late
2019
17 d late
← before the deadline
after the deadline →
Financials · fiscal year 2024, micro schema
Equity
€47k▲ 107%
2023 · €23k
2018: €1k
2019: €58k
2020: €60k
2021: €14k
2022: €25k
2023: €23k
2018 → 2024
Total assets
€523k▲ 201%
2023 · €174k
2018: €177k
2019: €329k
2020: €165k
2021: €102k
2022: €90k
2023: €174k
2018 → 2024
Net result
€24k
2023 · €-3k
2018: €-7k
2019: €78k
2020: €2k
2021: €-46k
2022: €11k
2023: €-3k
2018 → 2024
Working capital
€-44k▼ 256%
2023 · €-13k
2018: €50k
2019: €91k
2020: €82k
2021: €21k
2022: €20k
2023: €-13k
2018 → 2024
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20202021202220232024Trend
Equity€60k-€14k▼ 76.9%€25k▲ 81.9%€23k▼ 11.2%€47k▲ 107%
Operating result€-55k-€-25k▲ 54.5%€15k€5k▼ 65.8%€55k▲ 966%
Net result€2k-€-46k€11k€-3k€24k
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2024; 2024 is 966% above 2023 and is the highest result in the available series.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €523k
Fixed assets
€440k▲ 272%
Current assets
€83k▲ 49.8%
Equity and liabilities €523k
Equity
€47k▲ 107%
Debt
€477k▲ 215%
The debt ratio rises from 87.0% to 91.1%. Equity and debt are higher.
Key figures and ratios
EBITDA
€81k▲
2023 · €15k
Cash flow
€50k▲
2023 · €7k
Solvency
8.9%▼
2023 · 13.0%
Current ratio
0.65▼
2023 · 0.82
Quick ratio
0.65▼
2023 · 0.82
Debt / equity
10.23▲
2023 · 6.72
ROE
51.7%▲
2023 · -12.6%
ROA
4.6%▲
2023 · -1.6%
Interest coverage
3.62▲
2023 · 1.89
Debt
€477k▲
2023 · €151k
Debt ≤ 1 year
€128k▲
2023 · €68k
Debt > 1 year
€349k▲
2023 · €83k
Income taxes
€8k▲
2023 · €20
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2024 against 2023
Balance sheet
Code20232024
Assets
Total assets20/58€174k€523k▲
Fixed assets21/28€118k€440k▲
Tangible fixed assets22/27€117k€440k▲
Land and buildings22€115k€439k▲
Furniture and vehicles24€2k€662▼
Financial fixed assets28€1k-
Current assets29/58€56k€83k▲
Amounts receivable within one year40/41€56k€59k▲
Trade receivables40€41k€45k▲
Other amounts receivable41€14k€14k▲
Cash at bank and in hand54/58€1-
Deferred charges and accrued income490/1€166€24k▲
Equity and liabilities
Total equity and liabilities10/49€174k€523k▲
Equity10/15€23k€47k▲
Contributions10/11€59k€59k=
Profit (loss) carried forward14€-36k€-12k▲
Amounts payable17/49€151k€477k▲
Amounts payable after more than one year17€83k€349k▲
Financial debts170/4€83k€349k▲
Amounts payable within one year42/48€68k€128k▲
Current portion of amounts payable after more than one year42€13k€28k▲
Financial debts43€8k€6k▼
Credit institutions430/8€8k€6k▼
Trade debts44€7k€808▼
Suppliers440/4€7k€808▼
Taxes, remuneration and social security45€3k€19k▲
Taxes450/3€3k€19k▲
Other amounts payable47/48€38k€74k▲
Income statement
Code20232024
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€10k€26k▲
Other operating charges640/8€1k€3k▲
Gross operating margin9900€16k€84k▲
Operating profit (loss)9901€5k€55k▲
Financial income75/76B-€1
Recurring financial income75-€1
Financial charges65/66B€8k€22k▲
Recurring financial charges65€8k€22k▲
Profit (loss) for the period before taxes9903€-3k€32k▲
Income taxes67/77€20€8k▲
Profit (loss) for the period9904€-3k€24k▲
Profit (loss) for the period to be appropriated9905€-3k€24k▲
Appropriation of the result
Profit (loss) to be appropriated9906€-36k€-12k▲
Profit (loss) brought forward from the previous period14P€-33k€-36k▼
The notes to these accounts (10 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
2025
26-08
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 26 days late
2024
31-12
Financial
Back to profitnet €24k
Net result €24k after one loss-making year.
30-08
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 30 days late
2023
28-07
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
31-12
Financial
Back to profitnet €11k
Net result €11k after one loss-making year.
29-08
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 29 days late
2021
31-12
Financial
Weakest financial yearnet €-46k ▼2477%
Net result drops to €-46k, the lowest in the series; recovery starts the following year.
04-08
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema · 4 days late
2020
17-08
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema · 17 days late
2019
31-12
Financial
Back to profitnet €78k
Net result €78k after one loss-making year.
21-08
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema · 21 days late
2018
08-08
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema · 8 days late
2017
17-07
NBB filing
Annual accounts filed
fiscal year 2016 · micro schema
2016
14-06
NBB filing
Annual accounts filed
fiscal year 2015 · full schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
8 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Beaumont · 1 establishment unit since 2012
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Grand Place(BT) 236500 BeaumontGround area
88 m²
Building footprint
69 m²
Volume, LiDAR
795 m³
Parcel 56005A0434/00E000, Wallonia · tallest building 13.6 m, ±4 floors. Linked by address, not a title deed.
1 establishment unit
CF Pharma
since 20122.207.268.751
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 56005A0434/00E000 | Wallonia | 88 m² | 1 · 69 m² | 13.6 m · 4 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
OrthoPro De Wintere
BE 1004.864.966
Gent · Eq €47k
LABORIMPEX
BE 0420.691.374
Vorst · Eq €47k
LIMACOM PHARMA
BE 1018.736.758
Diepenbeek · Eq €46k
Kronos Dental
BE 0473.025.943
Overijse · Eq €46k
BRUPHARM PHARMALAB
BE 0785.641.404
Mons · Eq €45k
Of 1,898 companies in sector 46460 we hold annual accounts for 1,116. 469 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company (pre-2019)
Founded14-02-2012
Fiscal year end31-12
Activities, NACEBEL
46460Wholesale of pharmaceutical and medical goods
47730Retail sale of pharmaceutical products
47740Retail trade
47741Retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses
47750Retail sale of cosmetics and toilet articles
Sources
Crossroads Bank for EnterprisesNational Bank · 13 filingsAddress and cadastre registers
Data from official sources, last processed on 21-09-2026. Scores and ratios are computed by Checked and are not a credit decision.